ak 295 has been researched along with calpain in 12 studies
| Studies (ak 295) | Trials (ak 295) | Recent Studies (post-2010) (ak 295) | Studies (calpain) | Trials (calpain) | Recent Studies (post-2010) (calpain) |
|---|---|---|---|---|---|
| 13 | 0 | 0 | 7,019 | 25 | 2,422 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, A; Baker, KL; Bartus, RT; Dean, RL; Elliott, PJ; Harbeson, SL; Hayward, NJ; Li, Z; Sawyer, SD; Straub, JA | 1 |
| Bartus, RT; Hayward, NJ; McIntosh, TK; Murai, H; Perri, BR; Saatman, KE; Smith, DH | 1 |
| Banik, NL; Bartus, R; Hogan, EL; James, T; Matzelle, D | 1 |
| Bartus, RT; Chen, EY; Kordower, JH; Lynch, G | 1 |
| Andersson, AL; Bahr, BA; Blomgren, K; Hagberg, H; Hallin, U; Kawashima, S; McRae, A; Puka-Sundvall, M; Saido, TC | 1 |
| Bartus, RT; McIntosh, TK; Saatman, KE; Zhang, C | 1 |
| Culver, DG; Glass, JD; Wang, MS; Wu, Y | 1 |
| DeBiasi, RL; Edelstein, CL; Sherry, B; Tyler, KL | 1 |
| Bahr, BA; Blomgren, K; Hagberg, H; Karlsson, JO; Leverin, AL; Mallard, C; Wang, X; Zhu, C | 1 |
| Bahr, BA; Brown, QB; Caba, E; Kawasaki, B | 1 |
| Culver, DG; Davis, AA; Glass, JD; Powers, JC; Wang, MS; Wang, Q | 1 |
| Akdemir, O; Celik, O; Colak, A; Karaoğlan, A; Kaya, M; Sağmanligil, A; Sahan, E | 1 |
12 other study(ies) available for ak 295 and calpain
| Article | Year |
|---|---|
Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration.
Topics: Animals; Brain Ischemia; Calpain; Dipeptides; Dose-Response Relationship, Drug; Injections, Intra-Arterial; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 1994 |
Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat.
Topics: Animals; Brain Injuries; Calpain; Cognition Disorders; Cysteine Proteinase Inhibitors; Dipeptides; Disease Models, Animal; Male; Memory; Psychomotor Performance; Rats; Rats, Sprague-Dawley | 1996 |
New inhibitors of calpain prevent degradation of cytoskeletal and myelin proteins in spinal cord in vitro.
Topics: Animals; Calpain; Caseins; Cysteine Proteinase Inhibitors; Cytoskeletal Proteins; Dipeptides; Enzyme Inhibitors; Half-Life; Myelin Proteins; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Spinal Cord | 1998 |
Cortical ablation induces a spreading calcium-dependent, secondary pathogenesis which can be reduced by inhibiting calpain.
Topics: Animals; Antibodies; Calcium; Calpain; Cerebral Cortex; Cysteine Proteinase Inhibitors; Dipeptides; Geniculate Bodies; Immunohistochemistry; Male; Nerve Degeneration; Rats; Rats, Sprague-Dawley; Spectrin; Visual Cortex | 1999 |
Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Calcium-Binding Proteins; Calpain; Cell Membrane; Cysteine Proteinase Inhibitors; Dipeptides; Enzyme Activation; Female; Functional Laterality; Hypoxia; Male; Rats; Rats, Wistar; Up-Regulation | 1999 |
Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis.
Topics: Animals; Apoptosis; Behavior, Animal; Brain Injuries; Calpain; Cerebral Cortex; Cysteine Proteinase Inhibitors; Dipeptides; Male; Peptide Hydrolases; Rats; Rats, Sprague-Dawley; Spectrin | 2000 |
Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Axotomy; Calpain; Cells, Cultured; Chelating Agents; Cysteine Proteinase Inhibitors; Dipeptides; Egtazic Acid; Female; Ganglia, Spinal; Pregnancy; Rats; Rats, Sprague-Dawley; Vincristine; Wallerian Degeneration | 2000 |
Calpain inhibition protects against virus-induced apoptotic myocardial injury.
Topics: Animals; Apoptosis; Calpain; Caspase Inhibitors; Creatine Kinase; Cysteine Proteinase Inhibitors; Dipeptides; Mice; Myocarditis; Reoviridae Infections | 2001 |
Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"?
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Calpain; Carrier Proteins; Caspase 3; Caspases; Cysteine Proteinase Inhibitors; Dipeptides; Enzyme Activation; Enzyme Precursors; Female; Humans; Hypoxia; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Ischemia; Male; Microfilament Proteins; Protease Inhibitors; Rats; Rats, Wistar; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Substrate Specificity; Time Factors | 2001 |
Peptidyl alpha-keto amide inhibitor of calpain blocks excitotoxic damage without affecting signal transduction events.
Topics: Animals; Calpain; Cysteine Proteinase Inhibitors; Dipeptides; Hippocampus; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neurotoxins; NF-kappa B; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Spectrin | 2002 |
Calpain inhibition protects against Taxol-induced sensory neuropathy.
Topics: Animals; Antineoplastic Agents; Axons; Calpain; Caspases; Cell Death; Cell Line; Cells, Cultured; Dipeptides; Electrophysiology; Female; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microtubules; Nerve Degeneration; Neurons, Afferent; Paclitaxel; Rats; Rats, Inbred Strains | 2004 |
Calpain inhibitor AK 295 inhibits calpain-induced apoptosis and improves neurologic function after traumatic spinal cord injury in rats.
Topics: Animals; Apoptosis; Calpain; Dipeptides; Humans; Motor Activity; Neuroprotective Agents; Random Allocation; Rats; Rats, Wistar; Recovery of Function; Spinal Cord; Spinal Cord Injuries | 2009 |